STOCK TITAN

OptimizeRx Corporation - OPRX STOCK NEWS

Welcome to our dedicated page for OptimizeRx Corporation news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on OptimizeRx Corporation stock.

OptimizeRx Corporation (NASDAQ: OPRX) is a leading provider in the healthcare technology sector, offering digital health messaging solutions that enhance communication between pharmaceutical companies, healthcare providers, and patients. OptimizeRx specializes in the integration of electronic health records (EHR) to distribute financial assistance, educational materials, and clinical information directly at the point of care.

The company leverages its proprietary SampleMD and eCoupon technologies to expand the distribution of patient savings and support materials within the e-prescribing workflows of over 300,000 healthcare providers. These platforms enable healthcare providers to deliver real-time financial assistance and support to patients, thereby improving medication adherence and affordability.

OptimizeRx offers a range of products, including Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement. These solutions aim to help patients start and stay on their prescribed treatments while providing pharmaceutical companies with efficient ways to increase brand awareness and adherence.

Recently, OptimizeRx has undergone significant leadership changes. Gus Halas retired as Chairperson of the Board, succeeded by Lynn O’Connor Vos, a seasoned executive with extensive experience in healthcare IT and life sciences. Additionally, Catherine M. Klema was appointed to the Board, bringing her expertise in strategy, finance, and governance.

Financially, OptimizeRx is in a robust position. The company's revenue for FY2023 is estimated to exceed $68-$70 million, with adjusted EBITDA ranging between $3-$4 million. For 2024, the company anticipates revenue of at least $100 million due to a revised gross-to-net accounting treatment for certain revenue streams from its recent acquisition of Medicx Health.

The mission of OptimizeRx is to empower the healthcare community through innovative, tech-enabled communication solutions that improve patient care. By connecting over 60% of U.S. healthcare providers and millions of patients through its digital point-of-care network, OptimizeRx continues to deliver significant value to patients, healthcare professionals, and investors.

For more information, visit www.optimizerx.com

Rhea-AI Summary
OptimizeRx Corp. (OPRX) announces participation in investor conferences to engage with investors. The Company will be present at Barclays 26th Annual Global Healthcare Conference and 36th Annual ROTH Conference for discussions and one-on-one meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
-
Rhea-AI Summary
OptimizeRx Corp. (Nasdaq: OPRX) announces changes to its Board of Directors, with Gus Halas retiring and Lynn O’Connor Vos assuming the role of Chairperson. The company aims to align with its growth plans, leveraging Vos's expertise in healthcare technology and life sciences to lead the next phase of growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
-
Rhea-AI Summary
OptimizeRx Corp. (OPRX) announced preliminary unaudited financials for 2023, with expected revenue exceeding the guidance range of $68-$70 million. The company closed the year with 24 deals, driving a sequential improvement in key performance indicators. Adjusted EBITDA for the fourth quarter is expected to reach a new high, primarily due to a higher margin solution mix. The integration of the Medicx Health acquisition is ahead of expectations, with most activities expected to be completed by the end of the first quarter of 2024. CEO Will Febbo expressed confidence in achieving 2024 revenue guidance of at least $110 million and at least 10% adjusted EBITDA margins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.85%
Tags
none
Rhea-AI Summary
OptimizeRx Corp. (OPRX) executives will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 8-11, 2024. The presentation is scheduled for January 11, 2024, at 8:15 a.m. Pacific Time. Management will be available for institutional investor meetings on January 10th and 11th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags
conferences
-
Rhea-AI Summary
OptimizeRx Corp. reported Q3 2023 results, with revenue increasing 8% to $16.3 million and gross profit increasing 4% to $9.8 million. GAAP net loss per share was $(0.17), while non-GAAP net income per share was $0.09. The company completed the acquisition of Medicx Health after the quarter ended. OptimizeRx increased its guidance for 2023, expecting revenue between $68-$70 million and adjusted EBITDA between $3-$4 million. Preliminary 2024 guidance expects revenue of at least $110 million with an adjusted EBITDA margin of at least 10%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.31%
Tags
-
Rhea-AI Summary
OptimizeRx Corp. completes acquisition of Medicx Health, expands executive leadership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
Rhea-AI Summary
OptimizeRx preannounces preliminary third quarter 2023 results and announces acquisition of Medicx Health
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.01%
Tags
-
Rhea-AI Summary
OptimizeRx Corp. announces a new AI solution, the Dynamic Audience Activation Platform (DAAP), which expands its HCP engagement technology and improves market penetration. In a pilot program, the Company reported a 19% script lift among AI-identified HCPs. Revenue is expected to be tied to DAAP programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
Rhea-AI Summary
OptimizeRx announces expansion of its AI-enabled healthcare technology platform through partnerships with EHR providers and a telehealth platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
AI
Rhea-AI Summary
OptimizeRx Corp. (OPRX) reported a 186% YOY growth in RWD.AI-enabled portion of the core business, while non-core business lagged. Total revenue was $13.8 million, with a GAAP net loss of $(0.24) per share and non-GAAP net loss of $(0.01) per share for the second quarter of 2023. The company repurchased 526,999 shares at an average price of $14.27 per share in the second quarter of 2023. Cash, cash equivalents, and short-term investments totaled $62.7 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.76%
Tags

FAQ

What is the current stock price of OptimizeRx Corporation (OPRX)?

The current stock price of OptimizeRx Corporation (OPRX) is $5.49 as of January 3, 2025.

What is the market cap of OptimizeRx Corporation (OPRX)?

The market cap of OptimizeRx Corporation (OPRX) is approximately 99.3M.

What does OptimizeRx Corporation do?

OptimizeRx provides digital health messaging solutions that connect pharmaceutical companies, healthcare providers, and patients through electronic health records.

What are the main products offered by OptimizeRx?

OptimizeRx offers products such as Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement tools.

How does OptimizeRx help patients?

OptimizeRx aids patients by providing real-time access to financial assistance, educational materials, and clinical information directly through their healthcare providers.

Who is the current Chairperson of OptimizeRx?

Lynn O’Connor Vos is the current Chairperson of OptimizeRx, having succeeded Gus Halas.

What recent changes have occurred in OptimizeRx's leadership?

Gus Halas retired as Chairperson and was succeeded by Lynn O’Connor Vos. Catherine M. Klema was also appointed to the Board.

What are OptimizeRx's financial expectations for 2024?

OptimizeRx expects to achieve at least $100 million in revenue and an adjusted EBITDA of over $11 million for 2024.

How widely is OptimizeRx's technology adopted?

OptimizeRx's technology is integrated within the e-prescribing workflows of over 300,000 healthcare providers in the United States.

What is SampleMD?

SampleMD is OptimizeRx's proprietary technology that facilitates the distribution of patient savings and support materials within the e-prescribing workflow.

Where can I find more information about OptimizeRx?

More information can be found on their official website: www.optimizerx.com.

What is the mission of OptimizeRx?

OptimizeRx aims to empower the healthcare community through innovative, tech-enabled communication solutions that improve patient care.
OptimizeRx Corporation

Nasdaq:OPRX

OPRX Rankings

OPRX Stock Data

99.29M
15.73M
13.29%
68.94%
5.44%
Health Information Services
Services-business Services, Nec
Link
United States of America
WALTHAM